Encoded Therapeutics has Introduced ETX101 for the Treatment of Patients with Dravet Syndrome
Encoded Therapeutics has introduced ETX101 for the treatment of SCN1A+ Dravet syndrome, a rare and severe genetic neurological disorder that begins in early childhood.
ETX101 is an investigational gene regulation therapy designed to increase the expression of the SCN1A gene and restore normal sodium channel function in inhibitory neurons. By addressing the underlying genetic mechanism of the disease, the therapy aims to reduce seizures and improve neurological function in patients with Dravet syndrome.
The Breakthrough Therapy Designation from the U.S. Food and Drug Administration is supported by findings from ongoing Phase 1/2 clinical studies evaluating ETX101 in patients with Dravet syndrome. Early results have indicated a durable reduction in seizure frequency and improvements in aspects of neurodevelopment following a single administration of the therapy.
ETX101 has previously received several regulatory recognitions from the FDA, including Regenerative Medicine Advanced Therapy (RMAT), Fast Track, Orphan Drug and Rare Paediatric Disease Designations. In addition, the therapy has been granted Orphan Drug Designation by the European Medicines Agency.
Dravet syndrome is a rare developmental and epileptic encephalopathy that typically begins during infancy. The condition is most often caused by loss-of-function mutations in the SCN1A gene and is characterised by severe and frequent seizures that are often resistant to treatment. Patients may also experience cognitive impairment, behavioural challenges and motor difficulties, leading to a significant lifelong disease burden.
ETX101 is delivered through a single intracerebroventricular injection and is designed to provide long-term therapeutic benefit by addressing the genetic cause of the disorder. The therapy continues to be evaluated in clinical studies as part of its ongoing development programme.
